Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab-Reference-Cited by-同舟云学术

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab

Published:2018-10-17 Issue:1 Volume:6 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Zahoor Haris,Barata Pedro C.,Jia Xuefei,Martin Allison,Allman Kimberly D.,Wood Laura S.,Gilligan Timothy D.,Grivas Petros,Ornstein Moshe C.,Garcia Jorge A.,Rini Brian I.

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-018-0425-8.pdf

Reference33 articles.

1. Zahoor H, Rini BI. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma. Expert Opin Emerg Drugs. 2016;21(4):431–40.

2. Choueiri TK. VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective. Curr Clin Pharmacol. 2011;6(3):164–8.

3. Albiges L, Salem M, Rini B, Escudier B. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am. 2011;25(4):813–33.

4. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. Journal of clinical oncology : official journal of the. Proc Am Soc Clin Oncol. 1995;13(3):688–96.

5. Carlo MI, Voss MH, Motzer RJ. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nature reviews Urol. 2016;13(7):420–31.

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The causal relationships of granulocytes and melanoma skin cancer: A univariable and multivariable Mendelian randomization study;Skin Research and Technology;2024-08

2. Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25);Clinical Genitourinary Cancer;2024-08

3. Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial;BMJ Oncology;2024-06

4. Machine Learning Model Based on the Neutrophil-to-Eosinophil Ratio Predicts the Recurrence of Hepatocellular Carcinoma After Surgery;Journal of Hepatocellular Carcinoma;2024-04

5. Frontier knowledge and future directions of programmed cell death in clear cell renal cell carcinoma;Cell Death Discovery;2024-03-05